Seeking Alpha

Shares of Hi-Tech Pharmacal (HITK -18.1%) fall off sharply after rival Wockhardt says it landed...

Shares of Hi-Tech Pharmacal (HITK -18.1%) fall off sharply after rival Wockhardt says it landed FDA approval for a generic copy of GlaxoSmithKline's Flonase nasal spray in a development that could dampen sales of the firm's own generic offering.
Comments (1)
  • Lucky they have more products.
    I wonder who is buying all the share that are being sold --which are well over a weeks worth.
    Hope the president is at the San Fran conference--maybe he can find a small company to buy or maybe a company that might find value in HITK or maybe buy back some of the outstanding shares with some of that horde of cash that is on the balance sheet.
    Lots of maybes-- but smart people make lemonade out of lemons
    10 Jan 2012, 03:56 PM Reply Like
DJIA (DIA) S&P 500 (SPY)